CARLSMED, INC.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
CARL$14.52-5.2%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
(in thousands, except for share amounts)
| Series A ConvertiblePreferred Stock · Series B ConvertiblePreferred Stock · Series C ConvertiblePreferred Stock · Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’ | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Equity (Deficit) | |
| Balance as of December 31, 2023 | 4,902,814 | $13,578 | 4,335,051 | $29,801 | — | $— | 3,970,811 | $— | $784 | $(46,914) | $(46,130) |
| Issuance of Series C convertible preferred stock, net of issuance costs of $172 | — | — | — | — | 3,586,091 | 38,328 | — | — | — | — | — |
| Issuance of common stock | — | — | — | — | — | — | 29,121 | — | 6 | — | 6 |
| Exercise of vested stock options | — | — | — | — | — | — | 43,506 | — | 12 | — | 12 |
| Stock-based compensation expense | — | — | — | — | — | — | — | — | 35 | — | 35 |
| Net loss | — | — | — | — | — | — | — | — | — | (5,447) | (5,447) |
| Balance as of March 31, 2024 | 4,902,814 | $13,578 | 4,335,051 | $29,801 | 3,586,091 | $38,328 | 4,043,438 | $— | $837 | $(52,361) | $(51,524) |
| Exercise of vested stock options | — | — | — | — | — | — | 19,957 | — | 11 | — | 11 |
| Stock-based compensation expense | — | — | — | — | — | — | — | — | 52 | — | 52 |
| Net loss | — | — | — | — | — | — | — | — | — | (6,277) | (6,277) |
| Balance as of June 30, 2024 | 4,902,814 | $13,578 | 4,335,051 | $29,801 | 3,586,091 | $38,328 | 4,063,395 | $— | $900 | $(58,638) | $(57,738) |
| Issuance of Series C convertible preferred stock, net of issuance costs of $73 | — | — | — | — | 1,304,032 | 14,519 | — | — | — | — | — |
| Deemed dividend related to issuance of Series C convertible preferred stock | — | — | — | — | — | — | — | — | (592) | — | (592) |
| Vesting of early exercised stock options | — | — | — | — | — | — | 38,829 | — | 45 | — | 45 |
| Exercise of vested stock options | — | — | — | — | — | — | 8,637 | — | 4 | — | 4 |
| Stock-based compensation expense | — | — | — | — | — | — | — | — | 66 | — | 66 |
| Net loss | — | — | — | — | — | — | — | — | — | (7,813) | (7,813) |
| Balance as of September 30, 2024 | 4,902,814 | $13,578 | 4,335,051 | $29,801 | 4,890,123 | $52,847 | 4,110,861 | $— | $423 | $(66,451) | $(66,028) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.